Avadel Pharmaceuticals reports Q1 EPS (5c), consensus (7c)

Reports Q1 revenue $52.511M, consensus $50.57M. “We are pleased with the strong progress achieved in the first quarter of 2025, as we have seen improvements across all patient demand metrics for LUMRYZ, including patient starts, persistency rates, and net patients on therapy. As a result, we are raising our full year 2025 guidance and expect $255 – $265 million in net revenue and 3,400 – 3,600 patients on therapy by year end,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals (AVDL). “The improvements we are seeing are driven by the investments we made at the beginning of the year to expand our customer-facing teams, allowing us to deliver more personalized support and strengthen engagement with both patients and providers. We continue to build momentum and remain confident in our ability to deliver our growth plan and unlock the billion-dollar potential of LUMRYZ.”